{'fraction_non_alphanumeric': 0.020361990950226245, 'fraction_numerical': 0.006787330316742082, 'mean_word_length': 5.23943661971831, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Erythropoietin: back to basics.

In this issue of Blood, Sinclair and colleagues1 and Swift and colleagues2 report that the Epo receptor is barely detectable in nonhematopoietic tissues, casting doubt on the role of Epo as a pleiotropic hormone. The results not only have relevance for off-label clinical trials using recombinant human Epo for tissue-protection, but have important implications regarding Epo9s alleged effects on tumor cells.